FLUENCY PLUS ENDOVASCULAR STENT GRAFT

System, Endovascular Graft, Arteriovenous (av) Dialysis Access Circuit Stenosis Treatment

FDA Premarket Approval P130029 S002

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the fluency plus endovascular stent graft. This device is indicated for use in the treatment of in-stent restenosis in the venous outflow of hemodialysis patients dialyzing by either an arteriovenous (av) fistula or av graft and for the treatment of stenosis in the venous outflow of hemodialysis patients dialyzing by an av graft.

DeviceFLUENCY PLUS ENDOVASCULAR STENT GRAFT
Classification NameSystem, Endovascular Graft, Arteriovenous (av) Dialysis Access Circuit Stenosis Treatment
Generic NameSystem, Endovascular Graft, Arteriovenous (av) Dialysis Access Circuit Stenosis Treatment
ApplicantBARD PERIPHERAL VASCULAR, INC.
Date Received2015-05-01
Decision Date2016-04-26
Notice Date2016-05-12
PMAP130029
SupplementS002
Product CodePFV
Docket Number16M-1223
Advisory CommitteeCardiovascular
Supplement TypePanel Track
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination Product No
Applicant Address BARD PERIPHERAL VASCULAR, INC. 1415 West 3rd St. tempe, AZ 85281
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P130029Original Filing
S011 2021-08-26 Real-time Process
S010 2021-07-09 30-day Notice
S009 2021-02-25 30-day Notice
S008 2020-05-01 30-day Notice
S007 2017-04-10 Normal 180 Day Track No User Fee
S006 2016-11-30 135 Review Track For 30-day Notice
S005
S004 2016-02-12 Normal 180 Day Track No User Fee
S003 2015-06-15 Special (immediate Track)
S002 2015-05-01 Panel Track
S001 2015-04-08 135 Review Track For 30-day Notice

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.